Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль
- Войти
- Зарегистрироваться

Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0
ClinicalTrialUtilities: обзор

Галерея

Copiktra (duvelisib): Drug Safety Communication - FDA Warns about Possible Increased Risk of Death and Serious Side Effects
Source: FDA - What's New: Drugs RSS Feed Published on 2022-06-30 By FDA
Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-06-30 By FDA
Vaccines Research
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-06-30 By FDA
Generic Drugs Program Activities Report - Monthly Performance
Source: FDA - What's New: Drugs RSS Feed Published on 2022-06-30 By FDA
Human medicines European public assessment report (EPAR): Caprelsa, vandetanib, Thyroid Neoplasms, Date of authorisation: 16/02/2012, Revision: 22, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-06-30
Human medicines European public assessment report (EPAR): Xelevia, sitagliptin, Diabetes Mellitus, Type 2, Date of authorisation: 21/03/2007, Revision: 34, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-06-30
FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)
Source: FDA - What's New: Drugs RSS Feed Published on 2022-06-30 By FDA
Coronavirus (COVID-19) Update: FDA Recommends Inclusion of Omicron BA.4/5 Component for COVID-19 Vaccine Booster Doses
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-06-30 By FDA
Update: COVID-19 Vaccine Booster Composition
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-06-30 By FDA
COVID-19 Vaccines
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2022-06-30 By FDA
Draft report on the development of a harmonised approach to exposure assessment methodologies for residues from veterinary medicinal products, feed additives and pesticides residues in food of animal origin
Source: EMA - Regulatory and procedural guidelines (human and veterinary) Published on 2022-06-30
Human medicines European public assessment report (EPAR): Januvia, sitagliptin, Diabetes Mellitus, Type 2, Date of authorisation: 20/03/2007, Revision: 30, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-06-30
Human medicines European public assessment report (EPAR): Abiraterone Mylan, abiraterone acetate, Prostatic Neoplasms, Date of authorisation: 20/08/2021, Revision: 2, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-06-30
Human medicines European public assessment report (EPAR): Rapiscan, regadenoson, Myocardial Perfusion Imaging, Date of authorisation: 06/09/2010, Revision: 14, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-06-30
Human medicines European public assessment report (EPAR): Velmetia, sitagliptin,metformin, Diabetes Mellitus, Type 2, Date of authorisation: 16/07/2008, Revision: 32, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2022-06-30

Предыдущие записи

Тема: Scaffold от Danny Cooper.